Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week’s podcast edition of Five Must-Know Things: Lilly wows ADA with obesity results; Novo’s oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended June 30, 2023, including: Eli Lilly and Company wows ADA with obesity results; Novo Nordisk A/S’s oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio" - Scrip, June 26, 2023.)

(Also see "With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA" - Scrip, June 25, 2023.)

(Also see "A Momentous Day For DMD: Sarepta’s Elevidys Is First Gene Therapy Approved" - Scrip, June 22, 2023.)
(Also see "Biopharma Investors, Companies Learning To Adjust To Financial Market Realities" - Scrip, June 27, 2023.)

(Also see "Survive Or Fall: Korean Strategy In Changing Big Pharma Environment" - Scrip, June 27, 2023.)

Click here to explore this interactive content online.